FDA Advisory Panel CoI Statements Should Be More Transparent – NEJM
This article was originally published in The Gray Sheet
Executive Summary
FDA may need to change its conflict-of-interest policies for advisory panels, a column in the July 14 New England Journal of Medicine proposes